Page 198 - 2022_02-Haematologica-web

O. Abdulmalik et al.
40. Iyamu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol. 2003;122(6):1001-1008.
41. Zhang C, Li X, Lian L, et al. Anti-sickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents. Br J Haematol. 2004;125(6):788-795.
42. Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Br J Clin Pharmacol. 2002;54(6):627-634.
43. Kouta A, Hoppensteadt D, Bontekoe E, et al. Studies on tissue factor pathway inhibitor antigen release by bovine, ovine and porcine heparins following intravenous administration to non-human primates. Clin Appl Thromb Hemost. 2020; 26:1076029620951851.
44. Ghonim MA, Wang J, Ibba SV, et al. Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL- 4/signal transducer and activator of tran- scription 6/Janus kinase 1 pathway. J Trans Med. 2018;16(1):243.
45. Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagu- lation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012;18(2):195-200.
46. Hebbel RP, Hedlund BE. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Am J Hematol. 2018;93(3):321-325.
47. Estepp JH. Voxelotor (GBT440), a first-in- class hemoglobin oxygen-affinity modula- tor, has promising and reassuring preclini- cal and clinical data. Am J Hematol. 2018;93(3):326-329.
48. Winter WP, Seale WR, Yodh J. Interaction
of hemoglobin S with anionic polysaccha- rides. Am J Pediatr Hematol Oncol. Spring 1984;6(1):77-81.
49. Mohanty P, Jena RK, Sethy S. Variability of iron load in patients of sickle cell anaemia (HbSS): a study from Eastern India. J Clin Diagn Res. 2017;11(3):Ec19-ec22.
50. Shastri MD, Stewart N, Horne J, et al. Non- anticoagulant fractions of enoxaparin sup- press inflammatory cytokine release from peripheral blood mononuclear cells of aller- gic asthmatic individuals. PLoS One. 2015;10(6):e0128803.
51. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2):392-396.
52. Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221-230.
540
haematologica | 2022; 107(2)